CD19-directed CAR T-cell therapy, CD22 CAR T, Large B-cell lymphoma, Matthew J. Frank, NCT04088890
High CR rates are overcome by CD22-directed CAR T-Cell therapy against CD19 relapse in LBCL
In February 2023, a phase 1 trial at a single institution found that it was safe and possible for people with heavily pretreated large B-cell lymphoma (LBCL) to use CD22-directed chimeric antigen receptor (CAR) T-cell therapy aft..
Abecma, idecabtagene vicleucel, KarMMa-3
CAR T-cell treatment provides significant remission rates in clinical trials
Feb 2023: In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for triple-class exposed multiple myeloma. Abecma (idecabtagene vicleucel) chimeric antigen receptor ..
ASTCT, CIBMTR, Large B-cell lymphoma, Matthew Frank, Miltenyi Biotec, Stanford University
Novel treatment target for lymphoma patients who relapse after CAR-T therapy
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
anti-BCMA, CAR - T Cell therapy, CT103A, FDA, IASO Biotherapeutics, Innovent Biologics, orphan drug designation
CT103A, CAR T-cell Therapy, has been designated as an orphan drug by the FDA
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple myeloma. Orphan drug design..
CAR - T Cell therapy, China, IASO Biotherapeutics, multiple myeloma
CAR T-cell treatment from IASO Biotherapeutics receives new FDA approval
Feb 2023: IASO Biotherapeutics' investigational CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), CT103A, has received fast track and regenerative medicine advanced therapy designations from the U.S. Food and..
Brexucabtagene autoleucel, European Union, Gilead, Kite, Tecartus
Tecartus granted European marketing authorization for treatment of relapsed or refractory acute lymphoblastic leukemia
Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or refractory (r/r) B-cell precurs..
Blood Test, CAR - T Cell therapy, JAMA Oncology, neurofilament light chain, Neurotoxic Complications, Washington University
CAR T-Cell therapy complications can be predicted by a simple blood test
Sept 2022: The treatment of various tumours has been transformed by cell-based immunotherapy, often known as CAR-T cell therapy. In order to target and combat specific forms of leukaemia and lymphoma, the treatment employs genetic..
New test to determine whether CAR T-Cell therapy will work for lymphoma patients
Sept 2022: According to a study published in the Journal of Clinical Investigation, an engineer at the University of Houston (UH) may have discovered a mechanism to identify which lymphoma patients are most likely to respond to c..
ACT Therapeutics, Brian Ho-sung Min, GenScript ProBio, Seogkyoung-Kong, Seoul, South Korea
A memorandum of understanding (MOU) has been signed by GenScript ProBio to form a strategic partnership with ACT Therapeutics to develop new CAR-T cell therapies
July 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting so..
CAR - T Cell therapy, CARsgen Therapeutics Co, Daiichi Sankyo Company, DLBCL, Emergen Research, Limited, Novartis AG
CAR T-Cell therapy market will grow at phenomenal rate in next 8 years
July 2022: According to the most recent research conducted by Emergen Research, the global market for CAR T-cells therapy reached a size of USD 1.29 billion in 2021 and is expected to register a revenue CAGR of 24.9 percent ..